Robert E. Bancroft - 14 May 2025 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Role
President & CEO, Director
Signature
/s/ Alexander Wilson, as attorney-in-fact for Robert E. Bancroft
Issuer symbol
AEON
Transactions as of
14 May 2025
Transactions value $
$0
Form type
4
Filing time
16 May 2025, 16:17:08 UTC
Previous filing
01 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bancroft Robert E. President & CEO, Director C/O AEON BIOPHARMA, INC., 5 PARK PLAZA, SUITE 1750, IRVINE /s/ Alexander Wilson, as attorney-in-fact for Robert E. Bancroft 16 May 2025 0002066370

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AEON Class A Common Stock Award $0 +177K $0.00 177K 14 May 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Class A Common Stock for each RSU upon vesting. 25% of the RSUs shall vest on each anniversary of April 29, 2025.